![](/images/graphics-bg.png)
Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease
المؤلفون المشاركون
Lopalco, Giuseppe
Sota, Jurgen
Bellisai, Francesca
Vitale, Antonio
Berlengiero, Virginia
Ciarcia, Luisa
Ricco, Nicola
Barneschi, Sara
Mourabi, Mariam
Marzo, Chiara
Cantarini, Luca
Frediani, Bruno
Iannone, Florenzo
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-10-15
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Background.
Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still’s disease (AOSD).
However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case series.
Patients and Methods.
Patients classified with AOSD according to Yamaguchi criteria and treated with CAN were consecutively enrolled.
Their clinical and therapeutic data were retrospectively collected and statistically analysed to assess the role of CAN as a therapeutic opportunity in AOSD patients in terms of clinical and laboratory disease control along with corticosteroid-sparing effect.
Results.
Nine AOSD patients (8 females and 1 male) treated with CAN for 15.00±12.3 months were enrolled.
Resolution of clinical manifestations was reported in 8/9 cases at the 3-month assessment; a significant decrease in the number of tender joints (p=0.009), swollen joints (p=0.027), and disease activity score on 28 joints-C-reactive protein (DAS28-CRP) (p=0.044) was observed during the study period.
The systemic score of disease activity significantly decreased at the 3-month and 6-month assessments and at the last visit compared to the start of treatment (p=0.028, p=0.028, and p=0.018, respectively).
The daily corticosteroid dosage was significantly reduced at the 3-month and at the last follow-up visits (p=0.017 and p=0.018, respectively).
None of the patients experienced adverse events or severe adverse events during the follow-up.
Conclusions.
CAN has shown prompt and remarkable effectiveness in controlling AOSD activity in a real-life contest, with a significant glucocorticoid-sparing effect and an excellent safety profile.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Vitale, Antonio& Berlengiero, Virginia& Sota, Jurgen& Ciarcia, Luisa& Ricco, Nicola& Barneschi, Sara…[et al.]. 2020. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease. Mediators of Inflammation،Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1192016
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Vitale, Antonio…[et al.]. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease. Mediators of Inflammation No. 2020 (2020), pp.1-7.
https://search.emarefa.net/detail/BIM-1192016
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Vitale, Antonio& Berlengiero, Virginia& Sota, Jurgen& Ciarcia, Luisa& Ricco, Nicola& Barneschi, Sara…[et al.]. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease. Mediators of Inflammation. 2020. Vol. 2020, no. 2020, pp.1-7.
https://search.emarefa.net/detail/BIM-1192016
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1192016
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)